Madrigal Pharmaceuticals, Inc.
NASDAQMadrigal Pharmaceuticals posted Q1 2026 results today that landed above expectations on both lines — yet the stock fell 3% on the session to close at $502.47, and is down nearly 9% over the past month. The disconnect between a clean beat and a negative price reaction is the week's central tension. Revenue of $311.3M topped the $302.3M consensus estimate. EPS of -$3.25 beat the…
Snapshot as of 7 May 2026
Madrigal Pharmaceuticals posted Q1 2026 results today that landed above expectations on both lines — yet the stock fell 3% on the session to close at $502.47, and is down nearly 9% over the past month. The disconnect…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MDGL — free to start on ORTEX.
Sign up for free →Open MDGL on ORTEX